全文获取类型
| 收费全文 | 330475篇 |
| 免费 | 30336篇 |
| 国内免费 | 22428篇 |
专业分类
| 耳鼻咽喉 | 3017篇 |
| 儿科学 | 3439篇 |
| 妇产科学 | 4942篇 |
| 基础医学 | 40695篇 |
| 口腔科学 | 5564篇 |
| 临床医学 | 46216篇 |
| 内科学 | 50556篇 |
| 皮肤病学 | 3094篇 |
| 神经病学 | 18855篇 |
| 特种医学 | 12078篇 |
| 外国民族医学 | 213篇 |
| 外科学 | 34129篇 |
| 综合类 | 50309篇 |
| 现状与发展 | 76篇 |
| 一般理论 | 20篇 |
| 预防医学 | 19839篇 |
| 眼科学 | 9743篇 |
| 药学 | 33102篇 |
| 422篇 | |
| 中国医学 | 17907篇 |
| 肿瘤学 | 29023篇 |
出版年
| 2024年 | 3954篇 |
| 2023年 | 6742篇 |
| 2022年 | 13522篇 |
| 2021年 | 16708篇 |
| 2020年 | 12811篇 |
| 2019年 | 11019篇 |
| 2018年 | 11492篇 |
| 2017年 | 10039篇 |
| 2016年 | 9495篇 |
| 2015年 | 14433篇 |
| 2014年 | 17870篇 |
| 2013年 | 15373篇 |
| 2012年 | 22881篇 |
| 2011年 | 25813篇 |
| 2010年 | 15904篇 |
| 2009年 | 12249篇 |
| 2008年 | 17016篇 |
| 2007年 | 17020篇 |
| 2006年 | 17050篇 |
| 2005年 | 16778篇 |
| 2004年 | 10666篇 |
| 2003年 | 9757篇 |
| 2002年 | 8442篇 |
| 2001年 | 7465篇 |
| 2000年 | 8271篇 |
| 1999年 | 9007篇 |
| 1998年 | 5476篇 |
| 1997年 | 5498篇 |
| 1996年 | 4338篇 |
| 1995年 | 3925篇 |
| 1994年 | 3213篇 |
| 1993年 | 2097篇 |
| 1992年 | 2827篇 |
| 1991年 | 2415篇 |
| 1990年 | 2118篇 |
| 1989年 | 1861篇 |
| 1988年 | 1563篇 |
| 1987年 | 1353篇 |
| 1986年 | 1108篇 |
| 1985年 | 912篇 |
| 1984年 | 527篇 |
| 1983年 | 373篇 |
| 1982年 | 242篇 |
| 1981年 | 238篇 |
| 1980年 | 190篇 |
| 1979年 | 221篇 |
| 1978年 | 82篇 |
| 1977年 | 89篇 |
| 1974年 | 102篇 |
| 1973年 | 83篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
941.
942.
943.
Evaluation of Quality of Life Using EORTC QLQ‐BM22 in Patients with Bone Metastases after Treatment with Magnetic Resonance Guided Focused Ultrasound 
下载免费PDF全文
下载免费PDF全文 Zheng‐qi Chen MD Chong‐ren Wang MD Xiao‐jun Ma MD Wei Sun MD Jia‐kang Shen MD Meng‐xiong Sun MD Ze‐ze Fu MD Ying‐qi Hua MD Zheng‐dong Cai MD 《Orthopaedic Surgery》2018,10(3):264-271
Objective
To reveal the alterations in quality of life (QOL) in bone metastases patients after magnetic resonance guided focused ultrasound (MRgFUS).Methods
This retrospective study enrolled 26 patients diagnosed with bone metastases. Patients had various primary malignant tumors and tumor lesions in different locations. All patients received MRgFUS for bone metastasis. Each focal spot sonication pulse that was applied to create energy deposition lasted 20 s and was performed at a frequency of 1.05 MHz. The visual analog scale (VAS) was used to measure pain level and the EORTC QLQ‐BM22 was applied to evaluate QOL for 12 months. The lower the QLQ‐BM22 score, the better the QOL of patients.Results
The painful site subscale of the EORTC QLQ‐BM22 was observed without significant change. Significant reductions in the functional subscales were observed after therapy compared with the baseline. The functional interference was reduced significantly during the first 12 months. From the 2‐month time point onwards, the pain characteristics subscale also decreased significantly. VAS scores had decreased by 40.8% 1 month after the operation and had decreased 10.9% compared with VAS scores preoperation. Scores for pain characteristics decreased by 28.8% after the operation and the scores were still down by 10.8% 1 year after the treatment. VAS scores indicated a significant reduction in pain over the course of the research until the 12‐month time point follow‐up compared with the baseline.Conclusion
MRgFUS therapy improved the QOL of patients with bone metastasis by relieving bone pain.944.
945.
P. Kong L. Chen X. Shi H. Pan M. Yu H. Ge J. Zhu G. Ma L. Li Q. Ding W. Zhou S. Wang 《Diagnostic and interventional imaging》2018,99(12):783-791
Purpose
To evaluate the mechanism for enhancing cell death induced by microwave ablation (MWA) combined with doxorubicin treatment in breast cancer cells.Materials and methods
Different temperatures of heat treatment were used to mimic the tumor affected by sublethal heat during MWA in vitro. Breast cancer cells were treated at 43 °C and 45 °C, with or without doxorubicin. Cell viability, apoptosis, and intracellular reactive oxygen species (ROS) were evaluated in MDA-MB-231 and SUM-1315 cells. Nude mice breast cancer models were randomly divided into control, MWA, doxorubicin, and combined treatment groups. Tumor apoptosis and DNA damage were evaluated in these groups.Results
The combined group had lower cell viability than the heat or doxorubicin group (all P < 0.05), and enhanced apoptosis rate was observed in the combined group compared to others (all P < 0.01) in MDA-MB-231 and SUM-1315. Increased capase3 (all P < 0.01) and decreased Bcl-Xl (all P < 0.01) were detected after combined therapy compared to single treated group in vitro. The raisedCaspase3 and DNA damage marker histone H2A.X induced by combined treatment were also approved in the nude mice models. Combined treatment promoted ROS generation compared to doxorubicin or MWA treatment (all P < 0.01). NF-κB expression in the combined group was higher than that of the single treatment group (all P < 0.05). N-acetylcysteine (NAC), a ROS scavenger, partly restrained the combined treatment induced cell proliferation inhibition, Caspase3 and NF-κB compared to doxorubicin treatment (all P < 0.05).Conclusion
MWA combined with doxorubicin promote cell death via ROS induced cell apoptosis and DNA damage. Increasing ROS has potential for improving the efficiency of combined treatment. 相似文献946.
947.
948.
949.
950.